November 8, 2018 : Latest SGLT-2 Inhibitors News

• Empagliflozin as First Line in Patients with Type 2 and Fatty Liver Disease
• Dapagliflozin Use in Managing Type 1 Diabetes
• Sotagliflozin Shows Promise As Adjunct To Insulin Therapy
• Sotagliflozin As Adjunct Therapy for People with Type 1 to Increase Time in Target Range

This week the Food and Drug Administration has approved the product canagliflozin to reduce the risk of major adverse cardiovascular events, including heart attack, stroke or death due to a cardiovascular cause in adults with Type 2 diabetes who have established cardiovascular disease. Although we are all familiar with the cardiovascular benefits of the SGLT-2 Inhibitors, this is the first time the FDA has said that an SGLT-2 Inhibitor can reduce the risk.

The good things about this class of drugs continue to increase, as you can see in this month’s Therapy Edition.

Dave Joffe

Editor-in-chief

Multiple studies find drug to be first diabetes medication to show significant reduction of liver fat.

Adding an SGLT2 inhibitor helps lower HbA1c and decrease variability in glucose ranges among people with type 1 diabetes.

New SGLT1/SGLT2 inhibitor lowers HbA1c and has less hypoglycemia episodes among people who have type 1 diabetes.

Researchers seek development of drug therapies and technologies to assist in achieving additional time in glucose target range and less hypoglycemia.